A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Recruiting · Phase 1, Phase 2 · NCT06330064
Conditions: Recurrent or Metastatic Solid Tumors
At a glance
- Research payments reported, 2025
- $3.5M
- U.S. investigators named
- 18
- Sites paid
- 19
- Planned or actual enrollment
- 680
About the trial
- Sponsor
- Daiichi Sankyo (with Merck Sharp & Dohme LLC)
- Tested
- Ifinatamab deruxtecan (drug)
- Dates
- Started 2024-04-10; completion 2028-07-25
- Results posted
- Not yet
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); adenocarcinoma of esophagus, gastroesophageal junction, and stomach (Ad-Eso/GEJ/gastric); urothelial carcinoma (UC); ovarian cancer (OVC); cervical cancer (CC); biliary tract cancer (BTC); human epidermal growth factor 2 (HER2)-low breast cancer (BC); HER2 immunohistochemistry (IHC) 0 BC; cutaneous melanoma; and neuroendocrine carcinoma (NEC).
From ClinicalTrials.gov, last updated 2026-10-26. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $3.5M in research payments for this study in 2025 (1,537 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- David Berz, MD, PHD, MPH Hematology & Oncology · Los Angeles, CA
- Sungwon R. Kyung, M.D. Hematology & Oncology · Los Angeles, CA
- Lisa S. Wang, M.D. Hematology & Oncology · Whittier, CA
- Ira A. Oliff, MD Hematology & Oncology · Skokie, IL
- Geraldine H. O'sullivan Coyne, M.D, PHD Medical Oncology · Bethesda, MD
- Deanna G. Teoh, M.D. Gynecologic Oncology · Minneapolis, MN
- Kristen R. Spencer, D.O. Medical Oncology · New Brunswick, NJ
- Dan Costin, MD Hematology & Oncology · White Plains, NY
- James D'olimpio Hematology & Oncology · Lake Success, NY
- Deborah B. Doroshow, M.D., PH.D. Medical Oncology · New York, NY
- Stephen E. Depasquale, M.D. Gynecologic Oncology · Chattanooga, TN
- Axel Grothey, M.D. Hematology & Oncology · Germantown, TN
- Meredith S. Pelster, M.D. Hematology & Oncology · Nashville, TN
- Charles L. Cowey, M.D. Medical Oncology · Dallas, TX
- Leonardo Forero, MD Medical Oncology · Amarillo, TX
- Andrew A. Jackson, MD Hematology & Oncology · Shenandoah, TX
- Vaia Florou, MD Hematology & Oncology · Salt Lake City, UT
- Alexander I. Spira, M.D. Medical Oncology · Fairfax, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Valkyrie Clinical Trials $828,307
- South Texas Accelerated Research Therapeutics Llc $428,431
- Sarah Cannon Research Institute $391,134
- Los Angeles Hematology Oncology Medical Group $322,181
- Clinical Research Alliance $318,032
- Regents of the University of Minnesota $310,141
- West Cancer Center and Research Institute-East Campus $214,149
- Icahn School of Medicine at Mount Sinai $204,501
- Biomedical Research Alliance of New York LLC $142,702
- Orchard Healthcare Research $120,399
- University of Utah Hospital and Clinics, UT $85,696
- New York University $65,734
- Pih Health Hospital-Whittier, CA $60,167
- Virginia Cancer Specialists Fairfax $30,500
- Erlanger Health $21,520
- Los Angeles Cancer Network $4,148
- Texas Oncology-Amarillo Cancer Center $1,062
- The West Clinic $357
- White Plains Hospital Center, NY $195
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.